血清可溶性白细胞介素2受体与恶性肿瘤相关性研究  

The Study on the Correlation Between the Levels of Serum SIL-2R and Malignant Tumors

作　　者：辛华雯[1] 贾菊凤[1] 王润帮[1] 

机构地区：[1]广州军区武汉总医院临床药理科,武汉430070

出　　处：《中国肿瘤临床与康复》1999年第4期37-38,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的　探讨血清可溶性白细胞介素２ 受体（ＳＩＬ－ ２Ｒ）与恶性肿瘤临床分期、临床疗效的关系。方法　采用双抗体夹心ＥＬＩＳＡ法测定了８２例恶性肿瘤患者血清ＳＩＬ－ ２Ｒ水平。结果　８ 种不同恶性肿瘤患者血清ＳＩＬ－ ２Ｒ水平（６０８．０±２７５．７～１１３５．０±６５７．６Ｕ／ｍ ｌ）较之健康对照组（２５０．０±１２８．９Ｕ／ｍ ｌ）均明显升高，且与临床分期及临床疗效密切相关。结论　血清ＳＩＬ－ ２Ｒ检测有助于判断恶性肿瘤患者临床疗效、病情严重程度及估计预后。? Objective To explore the relationship between the levels of serum soluble IL-2 receptor (SIL-2R) and clinical stages,therapeutic effects on malignant tumors.Methods The levels of serum SIL-2R in 82 patients with different types of malignant tumors were dertermined with ELISA method.Results The levels of serum SIL-2R rose remarkably (608.0±275.7～1135.0±657.6U/ml) among patients suffering from tumors as compared with the normal persons (250.0±128.9U/ml)(P<0.01);the levels of serum SIL-2R of patients with malignancy had a significant correlation with clininal stages and therapeutic effects.Conclusion The determination of serum SIL-2R can benefit the estimation about therapeutic effects,the severity of the disease and prognosis of malignant tumors. 〔

关 键 词：恶性肿瘤 可溶性IL-2受体 

分 类 号：R730.21[医药卫生—肿瘤]